[Does epilepsy surgery really lower mortality?]

Détails

ID Serval
serval:BIB_8D575CB61F35
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
[Does epilepsy surgery really lower mortality?]
Périodique
Neurochirurgie
Auteur⸱e⸱s
Ryvlin P., Montavont A.
ISSN
0028-3770 (Print)
ISSN-L
0028-3770
Statut éditorial
Publié
Date de publication
05/2008
Volume
54
Numéro
3
Pages
282-6
Langue
anglais
Notes
Ryvlin, P
Montavont, A
fre
English Abstract
Review
France
Neurochirurgie. 2008 May;54(3):282-6. doi: 10.1016/j.neuchi.2008.02.047. Epub 2008 Apr 16.
Résumé
Patients with epilepsy suffer from a two to three fold increased death rate as compared to age and sex matched control population. This increased risk culminate to five fold in patients with drug resistant partial epilepsy eligible for epilepsy surgery, with the majority of deaths classified as sudden unexpected death in epilepsy (SUDEP). The pathophysiology of SUDEP remains uncertain, but all witnessed cases occurred during or immediately after a seizure. Several studies have evaluated the impact of epilepsy surgery on the risk of seizure related death and SUDEP. Four series have concentrated on operated patients, and have compared the death rates in those seizure free and non seizure free post-operatively. Three of these studies reported a significantly lower risk of SUDEP in patients cured by surgery as compared to those still seizing. Four other series have compared the mortality in surgically versus medically treated patients with refractory partial epilepsy. Three of these studies failed to show any significant difference in death or SUDEP rates between operated and and non operated patients. All the above series suffer various types of methological limitations, hampering any definite conclusion regarding the impact of epilepsy surgery on mortality. The launching of novel and large multicentric studies, which address the pitfalls of prior series, should allow to provide conclusive results within the next three years.
Mots-clé
Anticonvulsants/therapeutic use, Drug Resistance, Epilepsy/drug therapy/*mortality/*surgery, Humans, *Neurosurgical Procedures, Temporal Lobe/pathology/surgery, Treatment Outcome
Pubmed
Création de la notice
29/11/2018 12:37
Dernière modification de la notice
20/08/2019 14:51
Données d'usage